For Immediate Release: Exhibit 99.1 Investor Contact: Mark Melnyk 407-613-3327 mark.melnyk@hgv.com Media Contact: Lauren George 407-613-8431 lauren.george@hgv.com Hilton Grand Vacations Reports Second Quarter 2026 Results ORLANDO, Fla. (July 30, 2026) — Hilton Grand Vacations Inc. (NYSE: HGV) ("HGV" or "the Company") today reports its second quarter 2026 results. Second Quarter 2026 Results 1 "We delivered solid revenue and EBITDA growth in the second quarter driven by healthy tour growth and disciplined co ...

Exhibit 99.1 Allegro MicroSystems Reports First Quarter 2027 Results First Quarter Sales Increased by 27% Year-over-Year to $259 Million Manchester, NH, July 30, 2026 – Allegro MicroSystems, Inc. ("Allegro" or the "Company") (Nasdaq: ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced financial results for its first quarter ended June 26, 2026. "We began fiscal 2027 with strong momentum, delivering our sixth consecutive quarter ...

RICHMOND, Va. - July 30, 2026 - Altria Group, Inc. (NYSE: MO) today reports our 2026 second-quarter and first-half business results and narrows guidance for 2026 full-year adjusted diluted earnings per share (EPS). "In the second quarter, our operating companies continued to deliver against the priorities we outlined at the start of the year – advancing our smoke-free portfolio, strengthening our traditional tobacco businesses and delivering significant returns to shareholders," said Sal Mancuso, Altria's C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-38412 BRIDGEWATER BANCSHARES, INC. (Exact name of registrant as specified in its charter) ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Minnesota (State or other jurisdiction of incorporation or organization) 4450 Excelsior Boulevard, Suite 100 St. Louis Park, Minnesota (Address of principal executive offic ...

Huasheng International Holding Limited 華盛國際控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1323） 2025/2026 年報 Huasheng International Holding Limited 華盛國際控股有限公司 (Incorporated in the Cayman Islands with limited liability) 2025/2026 (Stock Code: 1323) 2025/2026 ANNUAL REPORT Huasheng International Holding Limited 華盛國際控股有限公司 ANNUAL REPORT 年報 Huasheng International Holding Limited 華盛國際控股有限公司 ANNUAL REPORT 年報 2025/2026 目錄 1 2025/26 年年報 2 公司資料 3 主席報告書 5 管理層討論與分析 14 董事及高級管理層簡介 16 企業管治報告 29 董事會報告 38 獨立核數師報告 43 綜合損益及其他全面收益報表 44 綜合財務狀況 ...

Exhibit 99.1 Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 and Raises Full- Year Outlook Strong Performance Underscores Growth Portfolio Momentum and Pipeline Progress (PRINCETON, N.J., July 30, 2026) – Bristol Myers Squibb (NYSE: BMY) today reports results for the second quarter of 2026. "The Growth Portfolio continues to deliver, achieving 15% growth in the quarter, and represents an expanding share of our overall business," said Christopher Boerner, Ph.D., board chair and chief e ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39094 PHATHOM PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 82-4151574 (State or other jurisdicti ...

Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Data presented at AACR and ASCO provide further validation of the potential of Bicycle technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D. Cash and cash equivalents of $510.1 million as of June 30, 2026, with expected cash runway into 2030 CAMBRIDGE, Englan ...

Exhibit 10.1 EXECUTION COPY AMENDMENT NO. 2 Dated as of July 28, 2026 to SEVENTH AMENDED AND RESTATED LOAN AGREEMENT Dated as of September 29, 2022 THIS AMENDMENT NO. 2 (this "Amendment") is made as of July 28, 2026 by and among Myers Industries, Inc., an Ohio corporation (the "Company"), MYE Canada Operations Inc. ("MYE Canada"), Scepter Canada Inc. ("Scepter" and, together with MYE Canada, the "Foreign Subsidiary Borrowers" and, together with the Company, the "Borrowers"), the financial institutions liste ...